NSPR INSPIREMD INC

InspireMD to Announce Third Quarter 2025 Financial Results

InspireMD to Announce Third Quarter 2025 Financial Results

MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.

Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD’s website or by registering below. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on InspireMD’s website.

Webcast: /starthere.jsp?ei=1738063&tp_key=c84683c4fd

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR.

We routinely post information that may be important to investors on our website. For more information, please visit .

Investor Contact:

Webb Campbell

Gilmartin Group LLC





EN
21/10/2025

Underlying

NSPRINSPIREMD INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INSPIREMD INC

 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healt...

InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14th at 12:45 pm Eastern Time (ET). A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD’s corporate website at About InspireMD, Inc.InspireMD seeks to utilize its proprietar...

11h / 54m 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results

InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results MIAMI, March 18, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the fourth quarter and year ended December 31, 2025. Recent Business Highlights: Generated revenue of $3.1 million in the fourth quarter of 2025, up 62% year-over-year.Sustained strong commercial traction in the U.S. with the launch of CGuard Prime and continued growth in int...

March 18, 2026 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Resu...

InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. A live audio webcast and an archive of the recording will be available throu...

March 9, 2026 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c...

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to one (1) new non-executive employee in the aggregate amount of 36,118 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of January 14, 2026, as an i...

January 20, 2026 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manus...

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC) The CGuard® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS) MIAMI, Jan. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that results from the Company’s C-GUARDIANS pivotal trial have now been published in ...

January 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch